腹腔注射 NK-92 改善早期与已成瘤卵巢癌模型异种移植瘤的生存

Ovarian cancer (OC) is a leading cause of gynecological cancer-related mortality. Management remains challenging as the disease frequently presents with intra-abdominal metastases at diagnosis, standard therapies can be associated with severe complications and disease recurrence is common. While cellular immunotherapy is increasingly investigated as a promising approach, the most effective routes of administration need to be established.

We have investigated NK cell therapeutics as a less toxic option and examined the permanent NK cell line, NK-92, as a suitable model.

Here, we report two xenograft mouse models with the ovarian adenocarcinoma cell line, SKOV-3, representing early-stage OC and late-stage OC with ascites to comprehensively evaluate the anti-cancer efficacy of different routes of NK-92 administration. Bioluminescence imaging, cell tracking with the IVIS system and animal survival were used to evaluate outcomes. The cells were administered via intraperitoneal (IP), intravenous (IV), or a combination of IP and IV routes.

We showed that NK-92 significantly increased animal survival when delivered IP (p = 0. 009 and p = 0. 018) or combined IP and IV (p = 0. 05 and p = 0. 017) in early and established OC xenografts, respectively, whereas intravenous delivery at similar doses had no effect on survival (p = 0. 665 and p = 0. 052) compared with untreated controls.

These findings, and our novel models, have potential implications for enhancing the clinical benefit of NK therapy in patients with advanced OC.